{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,19]],"date-time":"2026-09-19T07:17:30Z","timestamp":1789802250260,"version":"4.0.1"},"reference-count":51,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2025,1,1]],"date-time":"2025-01-01T00:00:00Z","timestamp":1735689600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,1,1]],"date-time":"2025-01-01T00:00:00Z","timestamp":1735689600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,9,13]],"date-time":"2024-09-13T00:00:00Z","timestamp":1726185600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100006108","name":"National Center for Advancing Translational Sciences","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100006108","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000867","name":"Robert Wood Johnson Foundation","doi-asserted-by":"publisher","award":["79439"],"award-info":[{"award-number":["79439"]}],"id":[{"id":"10.13039\/100000867","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000050","name":"National Heart Lung and Blood Institute","doi-asserted-by":"publisher","award":["K01 5K01HL155231"],"award-info":[{"award-number":["K01 5K01HL155231"]}],"id":[{"id":"10.13039\/100000050","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000862","name":"Doris Duke Charitable Foundation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000862","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["jhltonline.org","clinicalkey.fr","clinicalkey.jp","clinicalkey.es","clinicalkey.com.au","clinicalkey.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["The Journal of Heart and Lung Transplantation"],"published-print":{"date-parts":[[2025,1]]},"DOI":"10.1016\/j.healun.2024.09.007","type":"journal-article","created":{"date-parts":[[2024,9,16]],"date-time":"2024-09-16T06:34:31Z","timestamp":1726468471000},"page":"46-56","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":2,"title":["An integrated sampling strategy for therapeutic mycophenolic acid monitoring in lung transplant recipients"],"prefix":"10.1016","volume":"44","author":[{"given":"Laneshia K.","family":"Tague","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4540-7184","authenticated-orcid":false,"given":"Hephzibah","family":"Anthony","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Noha N.","family":"Salama","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ramsey R.","family":"Hachem","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Brian F.","family":"Gage","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrew E.","family":"Gelman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.healun.2024.09.007_bib1","doi-asserted-by":"crossref","first-page":"S394","DOI":"10.1016\/j.ajt.2024.01.017","article-title":"OPTN\/SRTR 2022 Annual data report: lung","volume":"24","author":"Valapour","year":"2024","journal-title":"Am J Transpl"},{"key":"10.1016\/j.healun.2024.09.007_bib2","doi-asserted-by":"crossref","first-page":"1060","DOI":"10.1016\/j.healun.2021.07.021","article-title":"The International Thoracic Organ Transplant Registry of the International Society for Heart and Lung Transplantation: thirty-eighth adult lung transplantation report - 2021; focus on recipient characteristics","volume":"40","author":"Chambers","year":"2021","journal-title":"J Heart Lung Transpl"},{"key":"10.1016\/j.healun.2024.09.007_bib3","doi-asserted-by":"crossref","first-page":"1023","DOI":"10.1016\/j.healun.2021.07.018","article-title":"The International Thoracic Organ Transplant Registry of the International Society for Heart and Lung Transplantation: twenty-fourth pediatric lung transplantation report - 2021; focus on recipient characteristics","volume":"40","author":"Hayes","year":"2021","journal-title":"J Heart Lung Transpl"},{"issue":"1","key":"10.1016\/j.healun.2024.09.007_bib4","doi-asserted-by":"crossref","first-page":"250","DOI":"10.1111\/ajt.15581","article-title":"Lung transplant outcomes are influenced by severity of neutropenia and granulocyte colony-stimulating factor treatment","volume":"20","author":"Tague","year":"2019","journal-title":"Am J Transpl"},{"key":"10.1016\/j.healun.2024.09.007_bib5","doi-asserted-by":"crossref","first-page":"1047","DOI":"10.1016\/j.healun.2018.05.002","article-title":"An intact microbiota is required for the gastrointestinal toxicity of the immunosuppressant mycophenolate mofetil","volume":"37","author":"Flannigan","year":"2018","journal-title":"J Heart Lung Transpl"},{"key":"10.1016\/j.healun.2024.09.007_bib6","doi-asserted-by":"crossref","first-page":"863","DOI":"10.1513\/AnnalsATS.202108-954RL","article-title":"Prescribing patterns and tolerability of mycophenolate and azathioprine in patients with nonidiopathic pulmonary fibrosis fibrotic interstitial lung disease","volume":"19","author":"Wong","year":"2022","journal-title":"Ann Am Thorac Soc"},{"key":"10.1016\/j.healun.2024.09.007_bib7","article-title":"Prevalence of mycophenolate mofetil discontinuation and subsequent outcomes in pediatric kidney transplant recipients: a PNRC study","volume":"28","author":"Moudgil","year":"2024","journal-title":"Pedia Transpl"},{"key":"10.1016\/j.healun.2024.09.007_bib8","doi-asserted-by":"crossref","DOI":"10.3389\/fneph.2022.933954","article-title":"The burden of gastrointestinal complaints in kidney transplant recipients using tacrolimus with and without mycophenolate mofetil: a randomized controlled study","volume":"2","author":"Fatly","year":"2022","journal-title":"Front Nephrol"},{"key":"10.1016\/j.healun.2024.09.007_bib9","doi-asserted-by":"crossref","DOI":"10.1111\/ctr.14671","article-title":"Tolerability of mycophenolate mofetil in elderly kidney transplant recipients: a retrospective cohort study","volume":"36","author":"Witek","year":"2022","journal-title":"Clin Transpl"},{"key":"10.1016\/j.healun.2024.09.007_bib10","doi-asserted-by":"crossref","first-page":"277","DOI":"10.1016\/j.healun.2012.11.028","article-title":"Tacrolimus with mycophenolate mofetil or sirolimus compared with calcineurin inhibitor-free immunosuppression (sirolimus\/mycophenolate mofetil) after heart transplantation: 5-year results","volume":"32","author":"Kaczmarek","year":"2013","journal-title":"J Heart Lung Transpl"},{"key":"10.1016\/j.healun.2024.09.007_bib11","doi-asserted-by":"crossref","first-page":"407","DOI":"10.18433\/jpps30505","article-title":"Limited sampling strategy for the estimation of mycophenolic acid and its acyl glucuronide metabolite area under the concentration-time curve in Japanese lung transplant recipients","volume":"22","author":"Tanaka","year":"2019","journal-title":"J Pharm Pharm Sci"},{"key":"10.1016\/j.healun.2024.09.007_bib12","doi-asserted-by":"crossref","first-page":"308","DOI":"10.1016\/j.phrs.2015.07.012","article-title":"Mycophenolic mofetil optimized pharmacokinetic modelling, and exposure-effect associations in adult heart transplant recipients","volume":"99","author":"Woillard","year":"2015","journal-title":"Pharm Res"},{"key":"10.1016\/j.healun.2024.09.007_bib13","doi-asserted-by":"crossref","first-page":"150","DOI":"10.1097\/FTD.0000000000000871","article-title":"Personalized therapy for mycophenolate: consensus report by the International Association of Therapeutic Drug Monitoring and Clinical Toxicology","volume":"43","author":"Bergan","year":"2021","journal-title":"Ther Drug Monit"},{"key":"10.1016\/j.healun.2024.09.007_bib14","doi-asserted-by":"crossref","first-page":"721","DOI":"10.1007\/s13318-021-00713-0","article-title":"A systematic review of multiple linear regression-based limited sampling strategies for mycophenolic acid area under the concentration-time curve estimation","volume":"46","author":"Sobiak","year":"2021","journal-title":"Eur J Drug Metab Pharm"},{"key":"10.1016\/j.healun.2024.09.007_bib15","doi-asserted-by":"crossref","first-page":"1035","DOI":"10.1016\/S1053-2498(01)00305-9","article-title":"Mycophenolic acid levels in pediatric heart transplant recipients receiving mycophenolate mofetil","volume":"20","author":"Dipchand","year":"2001","journal-title":"J Heart Lung Transpl"},{"key":"10.1016\/j.healun.2024.09.007_bib16","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1111\/bcpt.13743","article-title":"Pharmacokinetics of free and total mycophenolic acid in paediatric and adult renal transplant recipients: exploratory analysis of the effects of clinical factors and gene variants","volume":"131","author":"Liu","year":"2022","journal-title":"Basic Clin Pharm Toxicol"},{"key":"10.1016\/j.healun.2024.09.007_bib17","doi-asserted-by":"crossref","first-page":"917","DOI":"10.1016\/j.healun.2021.05.020","article-title":"Variants in mycophenolate and CMV antiviral drug pharmacokinetic and pharmacodynamic genes and leukopenia in heart transplant recipients","volume":"40","author":"Oreschak","year":"2021","journal-title":"J Heart Lung Transpl"},{"key":"10.1016\/j.healun.2024.09.007_bib18","doi-asserted-by":"crossref","DOI":"10.1111\/ctr.15142","article-title":"Real world experience with conversion from valganciclovir to letermovir for cytomegalovirus prophylaxis: letermovir reverses leukopenia and avoids mycophenolate dose reduction","volume":"37","author":"Jorgenson","year":"2023","journal-title":"Clin Transpl"},{"key":"10.1016\/j.healun.2024.09.007_bib19","unstructured":"Ferrer-Machin A, Vera-Cabrera M, Plasencia-Garcia I, Moreno-Garcia A, Perez-Mendez LI, Merino-Alonso J. Evaluation of neutropenia secondary to mycophenolate mofetil associated with valganciclovir in liver transplant patients. Farm Hosp. Feb 19 2021;45(2):77\u201381. Evaluacion de la neutropenia secundaria a micofenolato de mofetilo asociado a valganciclovir en pacientes trasplantados hepaticos. doi:10.7399\/fh.11571."},{"key":"10.1016\/j.healun.2024.09.007_bib20","doi-asserted-by":"crossref","DOI":"10.1016\/j.semarthrit.2023.152270","article-title":"Co prescription of anti-acid therapy reduces the bioavailability of mycophenolate mofetil in systemic sclerosis patients: a crossover trial","volume":"63","author":"Alex","year":"2023","journal-title":"Semin Arthritis Rheum"},{"key":"10.1016\/j.healun.2024.09.007_bib21","doi-asserted-by":"crossref","first-page":"1265","DOI":"10.1177\/0091270011412968","article-title":"Omeprazole impairs the absorption of mycophenolate mofetil but not of enteric-coated mycophenolate sodium in healthy volunteers","volume":"52","author":"Kees","year":"2012","journal-title":"J Clin Pharm"},{"key":"10.1016\/j.healun.2024.09.007_bib22","doi-asserted-by":"crossref","first-page":"1650","DOI":"10.1111\/j.1600-6143.2009.02682.x","article-title":"Proton pump inhibitors reduce mycophenolate exposure in heart transplant recipients-a prospective case-controlled study","volume":"9","author":"Kofler","year":"2009","journal-title":"Am J Transpl"},{"issue":"1","key":"10.1016\/j.healun.2024.09.007_bib23","first-page":"69","article-title":"Impact of SLCO1B3 polymorphisms on clinical outcomes in lung allograft recipients receiving mycophenolic acid","volume":"20","author":"Tague","year":"2019","journal-title":"Pharm J"},{"key":"10.1016\/j.healun.2024.09.007_bib24","doi-asserted-by":"crossref","first-page":"1539","DOI":"10.1124\/dmd.106.010553","article-title":"Influence of nonsynonymous polymorphisms of UGT1A8 and UGT2B7 metabolizing enzymes on the formation of phenolic and acyl glucuronides of mycophenolic acid","volume":"34","author":"Bernard","year":"2006","journal-title":"Drug Metab Dispos"},{"key":"10.1016\/j.healun.2024.09.007_bib25","doi-asserted-by":"crossref","first-page":"671","DOI":"10.1097\/FTD.0b013e3182708f84","article-title":"UGT1A9, UGT2B7, and MRP2 genotypes can predict mycophenolic acid pharmacokinetic variability in pediatric kidney transplant recipients","volume":"34","author":"Fukuda","year":"2012","journal-title":"Ther Drug Monit"},{"key":"10.1016\/j.healun.2024.09.007_bib26","doi-asserted-by":"crossref","first-page":"683","DOI":"10.1016\/j.cca.2011.12.003","article-title":"The association of the UGT1A8, SLCO1B3 and ABCC2\/ABCG2 genetic polymorphisms with the pharmacokinetics of mycophenolic acid and its phenolic glucuronide metabolite in Chinese individuals","volume":"413","author":"Geng","year":"2012","journal-title":"Clin Chim Acta"},{"key":"10.1016\/j.healun.2024.09.007_bib27","doi-asserted-by":"crossref","first-page":"1161","DOI":"10.1007\/s00228-007-0380-7","article-title":"Influence of SLCO1B1, 1B3, 2B1 and ABCC2 genetic polymorphisms on mycophenolic acid pharmacokinetics in Japanese renal transplant recipients","volume":"63","author":"Miura","year":"2007","journal-title":"Eur J Clin Pharm"},{"issue":"Suppl 1","key":"10.1016\/j.healun.2024.09.007_bib28","doi-asserted-by":"crossref","first-page":"S57","DOI":"10.1097\/FTD.0000000000000255","article-title":"Pharmacogenetic biomarkers predictive of the pharmacokinetics and pharmacodynamics of immunosuppressive drugs","volume":"38","author":"Picard","year":"2016","journal-title":"Ther Drug Monit"},{"key":"10.1016\/j.healun.2024.09.007_bib29","doi-asserted-by":"crossref","first-page":"327","DOI":"10.1016\/j.jchromb.2004.11.020","article-title":"Simultaneous determination of mycophenolic acid and its phenolic glucuronide in human plasma using an isocratic high-performance liquid chromatography procedure","volume":"817","author":"Indjova","year":"2005","journal-title":"J Chromatogr B Anal Technol Biomed Life Sci"},{"key":"10.1016\/j.healun.2024.09.007_bib30","doi-asserted-by":"crossref","first-page":"1497","DOI":"10.1093\/clinchem\/48.9.1497","article-title":"Limited sampling strategy for the estimation of mycophenolic acid area under the curve in adult renal transplant patients treated with concomitant tacrolimus","volume":"48","author":"Pawinski","year":"2002","journal-title":"Clin Chem"},{"key":"10.1016\/j.healun.2024.09.007_bib31","doi-asserted-by":"crossref","first-page":"1232","DOI":"10.1592\/phco.26.9.1232","article-title":"Limited sampling strategy for predicting area under the concentration-time curve of mycophenolic acid in adult lung transplant recipients","volume":"26","author":"Ting","year":"2006","journal-title":"Pharmacotherapy"},{"key":"10.1016\/j.healun.2024.09.007_bib32","doi-asserted-by":"crossref","first-page":"925","DOI":"10.1002\/jcph.125","article-title":"Limited sampling strategy of mycophenolic acid in adult kidney transplant recipients: influence of the post-transplant period and the pharmacokinetic profile","volume":"53","author":"Chaabane","year":"2013","journal-title":"J Clin Pharm"},{"key":"10.1016\/j.healun.2024.09.007_bib33","doi-asserted-by":"crossref","DOI":"10.3389\/fphar.2021.652333","article-title":"Limited sampling strategy for estimation of mycophenolic acid exposure in adult Chinese heart transplant recipients","volume":"12","author":"Xiang","year":"2021","journal-title":"Front Pharm"},{"key":"10.1016\/j.healun.2024.09.007_bib34","doi-asserted-by":"crossref","first-page":"304","DOI":"10.1097\/FTD.0000000000000165","article-title":"Limited sampling strategy for predicting area under the concentration-time curve for mycophenolic acid in Chinese adults receiving mycophenolate mofetil and tacrolimus early after renal transplantation","volume":"37","author":"Cai","year":"2015","journal-title":"Ther Drug Monit"},{"key":"10.1016\/j.healun.2024.09.007_bib35","doi-asserted-by":"crossref","first-page":"1684","DOI":"10.1002\/lt.21293","article-title":"Validation of limited sampling strategy for the estimation of mycophenolic acid exposure in Chinese adult liver transplant recipients","volume":"13","author":"Hao","year":"2007","journal-title":"Liver Transpl"},{"key":"10.1016\/j.healun.2024.09.007_bib36","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1097\/FTD.0b013e3182a37a1e","article-title":"Limited sampling model for advanced mycophenolic acid therapeutic drug monitoring after liver transplantation","volume":"36","author":"Langers","year":"2014","journal-title":"Ther Drug Monit"},{"key":"10.1016\/j.healun.2024.09.007_bib37","doi-asserted-by":"crossref","first-page":"1249","DOI":"10.1007\/s00228-019-02701-5","article-title":"Limited sampling strategy to predict mycophenolic acid area under the curve in pediatric patients with nephrotic syndrome: a retrospective cohort study","volume":"75","author":"Sobiak","year":"2019","journal-title":"Eur J Clin Pharm"},{"key":"10.1016\/j.healun.2024.09.007_bib38","doi-asserted-by":"crossref","first-page":"83","DOI":"10.2217\/pgs-2022-0101","article-title":"SLCO1B3 T334G polymorphisms and mycophenolate mofetil-related adverse reactions in kidney transplant recipients","volume":"24","author":"Zhong","year":"2023","journal-title":"Pharmacogenomics"},{"key":"10.1016\/j.healun.2024.09.007_bib39","doi-asserted-by":"crossref","first-page":"1111","DOI":"10.2217\/pgs-2021-0102","article-title":"SLCO1B3 polymorphisms and clinical outcomes in kidney transplant recipients receiving mycophenolate","volume":"22","author":"Schumacher","year":"2021","journal-title":"Pharmacogenomics"},{"key":"10.1016\/j.healun.2024.09.007_bib40","doi-asserted-by":"crossref","first-page":"1291","DOI":"10.1007\/s40262-021-01037-7","article-title":"The impact of genetic polymorphisms on the pharmacokinetics and pharmacodynamics of mycophenolic acid: systematic review and meta-analysis","volume":"60","author":"Na Takuathung","year":"2021","journal-title":"Clin Pharm"},{"issue":"1","key":"10.1016\/j.healun.2024.09.007_bib41","doi-asserted-by":"crossref","first-page":"e43","DOI":"10.1016\/j.jhep.2024.03.038","article-title":"Replyto: Comments on \"An open-label randomised-controlled trial of azathioprinevs. mycophenolate mofetil for the induction of remission in treatment-naiveautoimmune hepatitis","volume":"81","author":"Snijders","year":"2024","journal-title":"J Hepatol"},{"key":"10.1016\/j.healun.2024.09.007_bib42","article-title":"Mycophenolate mofetil for autoimmune cytopenias in children: high rates of response in inborn errors of immunity","volume":"11","author":"Berrueco","year":"2023","journal-title":"Front Pedia"},{"key":"10.1016\/j.healun.2024.09.007_bib43","article-title":"Long-term efficacy and safety of different corticosteroid courses plus mycophenolate mofetil for autoimmune encephalitis with neuronal surface antibodies without tumor","volume":"14","author":"Li","year":"2023","journal-title":"Front Immunol"},{"issue":"6","key":"10.1016\/j.healun.2024.09.007_bib44","doi-asserted-by":"crossref","first-page":"2202071","DOI":"10.1183\/13993003.02071-2022","article-title":"Rituximab and mycophenolate mofetil combination in patients with interstitial lung disease (EVER-ILD): a double-blind, randomised, placebo-controlled trial","volume":"61","author":"Mankikian","year":"2023","journal-title":"Eur Respir J"},{"key":"10.1016\/j.healun.2024.09.007_bib45","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1007\/s40262-013-0039-8","article-title":"Clinical pharmacokinetics and pharmacodynamics of mycophenolate in patients with autoimmune disease","volume":"52","author":"Abd Rahman","year":"2013","journal-title":"Clin Pharm"},{"key":"10.1016\/j.healun.2024.09.007_bib46","doi-asserted-by":"crossref","first-page":"4732","DOI":"10.1111\/bcp.15389","article-title":"Population pharmacokinetics and Bayesian estimation of mycophenolate mofetil in patients with autoimmune hepatitis","volume":"88","author":"Nanga","year":"2022","journal-title":"Br J Clin Pharm"},{"key":"10.1016\/j.healun.2024.09.007_bib47","doi-asserted-by":"crossref","first-page":"4","DOI":"10.2133\/dmpk.DMPK-13-RV-112","article-title":"Optimization of mycophenolic acid therapy using clinical pharmacometrics","volume":"29","author":"Dong","year":"2014","journal-title":"Drug Metab Pharm"},{"key":"10.1016\/j.healun.2024.09.007_bib48","doi-asserted-by":"crossref","first-page":"759","DOI":"10.2165\/11596380-000000000-00000","article-title":"Maximum a posteriori Bayesian estimation of mycophenolic acid area under the concentration-time curve: is this clinically useful for dosage prediction yet?","volume":"50","author":"Staatz","year":"2011","journal-title":"Clin Pharm"},{"key":"10.1016\/j.healun.2024.09.007_bib49","doi-asserted-by":"crossref","first-page":"224","DOI":"10.1097\/FTD.0b013e31819c077c","article-title":"Comparison of 3 estimation methods of mycophenolic acid AUC based on a limited sampling strategy in renal transplant patients","volume":"31","author":"Hulin","year":"2009","journal-title":"Ther Drug Monit"},{"key":"10.1016\/j.healun.2024.09.007_bib50","doi-asserted-by":"crossref","first-page":"1147","DOI":"10.2215\/CJN.02820707","article-title":"Pharmacokinetics of mycophenolate sodium and comparison with the mofetil formulation in stable kidney transplant recipients","volume":"2","author":"Cattaneo","year":"2007","journal-title":"Clin J Am Soc Nephrol"},{"key":"10.1016\/j.healun.2024.09.007_bib51","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1097\/TP.0b013e3181de9193","article-title":"Enteric-coated mycophenolate sodium versus mycophenolate mofetil maintenance immunosuppression: outcomes analysis of the United Network for Organ Sharing\/Organ Procurement and Transplantation Network database","volume":"90","author":"Irish","year":"2010","journal-title":"Transplantation"}],"container-title":["The Journal of Heart and Lung Transplantation"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S105324982401859X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S105324982401859X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,5,16]],"date-time":"2025-05-16T11:39:12Z","timestamp":1747395552000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S105324982401859X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,1]]},"references-count":51,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2025,1]]}},"alternative-id":["S105324982401859X"],"URL":"https:\/\/doi.org\/10.1016\/j.healun.2024.09.007","relation":{},"ISSN":["1053-2498"],"issn-type":[{"value":"1053-2498","type":"print"}],"subject":[],"published":{"date-parts":[[2025,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"An integrated sampling strategy for therapeutic mycophenolic acid monitoring in lung transplant recipients","name":"articletitle","label":"Article Title"},{"value":"The Journal of Heart and Lung Transplantation","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.healun.2024.09.007","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 The Authors. Published by Elsevier Inc. on behalf of International Society for Heart and Lung Transplantation.","name":"copyright","label":"Copyright"}]}}